It is important to note that since CETP and SGLT2 inhibitors are both oral drugs, their combination therapy represents an oral therapeutic strategy for treatment-resistant diabetes prior to use of injectable drugs such as insulin or glucagon-like peptide 1 (GLP1) receptor agonists (24). This evidence concerns the gene INS and diabetes mellitus.